Cite
MLA Citation
Alexander Kalin et al.. “A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.” Amyotrophic lateral sclerosis and frontotemporal degeneration, vol. 18, n.d., pp. 71–79. http://access.bl.uk/ark:/81055/vdc_100049374516.0x000061